Announcements Trials

Browse Landscape

Phase

Status

Completed 4 Terminated 2 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 36 Prostatic Neoplasms, Castration-Resistant 5 Neoplasm Metastasis 5 Metastatic Castration-Resistant Prostate Cancer 4 Neoplasms 3 Small Cell Lung Carcinoma 2 Prostatic Diseases 2 Prostate Adenocarcinoma 2 Adenocarcinoma 2 Uterine Cervical Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor 1 Sleep Initiation and Maintenance Disorders 1 Recurrence 1 Prostate Cancer Metastatic 1 Pathologic Complete Response 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1 Neoplasms by Site 1 Neoplasms by Histologic Type 1 Neoplasm, Residual 1 Neoadjuvant Therapy 1 Metastatic Hormone-sensitive Prostate Cancer 1 Metastatic Castration-resistant Prostate Neoplasms 1 Metastatic Castration-resistant Prostate Cancer (mCRPC) 1 Metastatic Castration-resistant Prostate Cancer 1 Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1 Metastatic Castrate-Resistant Prostate Cancer 1 Mesothelioma, Malignant 1 Melanoma 1

Interventions

Radiosurgery 3 Androgen Antagonists 3 pembrolizumab 1 fludrocortisone acetate 1 enzalutamide 1 darolutamide 1 cabazitaxel 1 Radiotherapy, Image-Guided 1 Radiotherapy 1 Prednisone 1 Pluvicto 1 Lutetium-177 1 Lutetium 1 Hydrocortisone 1 Gonadotropin-Releasing Hormone 1 Docetaxel 1 Dexamethasone 1 Carboplatin 1 Abiraterone Acetate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Prostate Cancer Metastatic × enzalutamide × Clear all

NCT06136624 2026-05-05

OMAHA-003

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡